Scarica l'app Stockscreener
13.39
7.87%
0.995
Precedente Chiudi:
$12.39
Aprire:
$12.36
Volume 24 ore:
174.82K
Relative Volume:
0.91
Capitalizzazione di mercato:
$291.76M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+33.97%
1M Prestazione:
+27.33%
6M Prestazione:
+11.88%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.32
$13.77
Intervallo di 1 settimana:
$9.18
$13.77
Portata 52W:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Confronta AARD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.40 | 269.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.04 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.38 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.11 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
902.94 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.16 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser
Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView
Aardvark Therapeutics initiated with a Strong Buy at Raymond James - TipRanks
Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK
Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
What risks investors should watch in Aardvark Therapeutics Inc. stockEarnings Trend Report & Real-Time Chart Breakout Alerts - BỘ NỘI VỤ
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - The Manila Times
Why Aardvark Therapeutics Inc. stock is seen as undervalued2025 Big Picture & Fast Gain Swing Alerts - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsJuly 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
From HERO To POWER: AARD Charts Bold Course In Obesity And Rare Disease Trials - RTTNews
Real time social sentiment graph for Aardvark Therapeutics Inc. - newser.com
Aardvark Therapeutics Reports Q3 2025 Financial Results - TipRanks
Is Aardvark Therapeutics Inc. forming a reversal patternGold Moves & Reliable Entry Point Alerts - newser.com
RBC Capital Maintains Aardvark Therapeutics (AARD) Outperform Recommendation - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock - Investing.com
Can Aardvark Therapeutics Inc. stock deliver sustainable ROEMarket Performance Report & Verified Momentum Stock Watchlist - Fundação Cultural do Pará
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital By Investing.com - Investing.com South Africa
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital - Investing.com Nigeria
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Aardvark Therapeutics, Inc. SEC 10-Q Report - TradingView
Aardvark (Nasdaq: AARD) aligns with FDA to lower HERO trial age to 10, runway into 2027 - Stock Titan
Is Aardvark Therapeutics Inc. building a consolidation baseJuly 2025 Sentiment & High Accuracy Buy Signal Tips - newser.com
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (NASDAQ: AARD) grants 4,881-share inducement option at $10.44 - Stock Titan
Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline - TipRanks
Is Aardvark Therapeutics Inc. forming a bottoming basePortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - newser.com
Aardvark Therapeutics Showcases Obesity Research at ObesityWeek - MSN
Is Aardvark Therapeutics Inc. stock attractive for income investorsWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Non sono disponibili dati finanziari per Aardvark Therapeutics Inc (AARD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Aardvark Therapeutics Inc Azioni (AARD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.72%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):